Overall Rating
Stock is slightly underperforming.
Stock's dividend yield is attractive.
This rating is directly related to the length and consistency of a company's dividend payouts.
Dividend payouts are consistent, but increases small.
Earnings estimates have been cut slightly.
Recent Headlines
- Dividend Stocks: The Week Ahead (AXP, PFE, T, FCX, MSFT, more)
Sun, Oct 19, 2008 - 20 Dividend Stocks Removed from Our Recommended List
Tue, Oct 7, 2008 - Pfizer Suffers Drug Setback, But a Deal May be in the Works (PFE)
Tue, Sep 9, 2008 - Pfizer Gives Thanks for the Weak Dollar (PFE)
Wed, Jul 23, 2008 - Is Pfizer's High Yield a Dividend Trap?
Wed, Jun 25, 2008
Profile & Recommendation
Company Profile
Pfizer (PFE) - pharmaceutical name that has struggled with lack of new blockbuster drugs lately. A dividend has been paid since 1901, and raised each year since 1968. Its Pharmaceutical segment offers products for cardiovascular and metabolic diseases, such as Lipitor for elevated cholesterol levels in the blood; Norvasc for hypertension; Caduet for cardiovascular events; Chantix/Champix for smoking cessation; and Exubera, the inhaled human insulin therapy for glycemic control. Its products for central nervous system disorders include Zoloft for various disorders; Geodon/Zeldox, a psychotropic agent; Aricept for Alzheimer's disease; and Lyrica for adjuctive therapy for adults with partial onsent epileptic seizures. This segment also offers Celebrex for osteoarthritis, adult rheumatoid arthritis, acute pain, menstrual pain, and familial adenomatous polyposis; Zithromax for bacterial infections; Vfend for serious and potentially fatal fungal infections, esophageal candidiasis, and blood stream infections in non-neutropenic patients; Zyvox for bacterial infections; and Viagra for erectile dysfunction; and Detrol for overactive bladder. In addition, it offers Camptosar, a therapy for metastatic colorectal cancer; Sutent, an oral multi-kinase inhibitor; Xalatan/Xalacom for open-angle glaucoma and ocular hypertension; Genotropin for various growth disorders; and Zyrtec for allergies and hives. The company was founded in 1849 and is headquartered in New York, New York.
Based on our rating criteria, this stock has achieved a "Neutral" rating. Stocks with a neutral rating are considered mediocre investments in terms of expected price growth and dividend payments.
Stock Notes
This large cap stock does not make an attractive dividend stock investment at this time.






Direct Competitors
RSS Feeds